Jude Fitzgibbon

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6735277/publications.pdf

Version: 2024-02-01

155 papers	8,020 citations	41344 49 h-index	53230 85 g-index
164 all docs	164 docs citations	164 times ranked	11452 citing authors

#	Article	IF	Citations
1	Acquired somatic variants in inherited myeloid malignancies. Leukemia, 2022, 36, 1377-1381.	7.2	8
2	KDM4C in GC lymphoma: a new piece of the epigenetic puzzle. Haematologica, 2022, , .	3.5	1
3	CKS1 inhibition depletes leukemic stem cells and protects healthy hematopoietic stem cells in acute myeloid leukemia. Science Translational Medicine, 2022, 14, .	12.4	8
4	Molecular Genetics in Indolent Lymphomas. Hematologic Malignancies, 2021, , 5-20.	0.2	0
5	Germline ETV6 variants: not ALL created equally. Blood, 2021, 137, 288-289.	1.4	0
6	Generation and Surgical Analysis of to Study NF-Î¹B-Driven Pathogenesis of Diffuse Large B Cell Lymphoma. Methods in Molecular Biology, 2021, 2366, 321-342.	0.9	0
7	KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas. Blood, 2021, 138, 370-381.	1.4	33
8	Drug ranking using machine learning systematically predicts the efficacy of anti-cancer drugs. Nature Communications, 2021, 12, 1850.	12.8	68
9	The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy. Haematologica, 2021, 106, 3004-3007.	3.5	29
10	Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. Nature Communications, 2021, 12, 6233.	12.8	17
11	Characterising Tumour and Microenvironmental Responses to R-CHOP in Immunocompetent Mouse Models of DLBCL. Blood, 2021, 138, 2401-2401.	1.4	0
12	The Paradoxical Efficacy of KDM6 Inhibition in Germinal Centre B-Cell Lymphomas. Blood, 2021, 138, 3289-3289.	1.4	0
13	An EZH2 Gene Expression Signature Is Predictive of Differential Efficacy of Chemotherapy Irrespective of EZH2 Mutation Status in Patients with Follicular Lymphoma Treated within the Gallium Trial. Blood, 2021, 138, 39-39.	1.4	1
14	Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit. Leukemia, 2020, 34, 1329-1341.	7.2	66
15	AML through the prism of molecular genetics. British Journal of Haematology, 2020, 188, 49-62.	2.5	17
16	Identification of Recurrent Mutations in the microRNA-Binding Sites of B-Cell Lymphoma-Associated Genes in Follicular Lymphoma. International Journal of Molecular Sciences, 2020, 21, 8795.	4.1	1
17	The Biological Basis of Histologic Transformation. Hematology/Oncology Clinics of North America, 2020, 34, 771-784.	2.2	4
18	Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 1. Hemato, 2020, 1, 10-22.	0.6	0

#	Article	IF	Citations
19	Recent Advancements in Hematology: Knowledge, Methods and Dissemination. Hemato, 2020, 1, 5-6.	0.6	0
20	A frameshift variant in specificity protein 1 triggers superactivation of Sp1-mediated transcription in familial bone marrow failure. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 17151-17155.	7.1	2
21	The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants. Nature Communications, 2020, 11, 1044.	12.8	81
22	Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphoma. Haematologica, 2020, 105, 318-321.	3.5	5
23	Mesenchymal niche remodeling impairs hematopoiesis via stanniocalcin 1 in acute myeloid leukemia. Journal of Clinical Investigation, 2020, 130, 3038-3050.	8.2	48
24	Systematic Evaluation of Somatic Cis-Regulatory Mutations in Follicular Lymphoma. Blood, 2020, 136, 26-27.	1.4	0
25	Transmission of diffuse large B-cell lymphoma by an allogeneic stem-cell transplant. Haematologica, 2019, 104, e174-e177.	3.5	5
26	Oncogenic Rag GTPase signalling enhances B cell activation and drives follicular lymphoma sensitive to pharmacological inhibition of mTOR. Nature Metabolism, 2019, 1, 775-789.	11.9	40
27	Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML. Science Advances, 2019, 5, eaaw4304.	10.3	28
28	Follicular lymphoma. Nature Reviews Disease Primers, 2019, 5, 83.	30.5	148
29	Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy. Blood, 2019, 134, 122-122.	1.4	41
30	Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel. Blood, 2019, 134, 2769-2769.	1.4	0
31	Predicting early relapse in follicular lymphoma: have we turned a corner?. Lancet Oncology, The, 2018, 19, 441-442.	10.7	1
32	Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells. Leukemia, 2018, 32, 1818-1822.	7.2	36
33	Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma. Leukemia, 2018, 32, 1261-1265.	7.2	87
34	Rituximab as a first step in tackling transformation. Lancet Haematology,the, 2018, 5, e326-e327.	4.6	0
35	Precision medicine and lymphoma. Current Opinion in Hematology, 2018, 25, 329-334.	2.5	8
36	GATA2 monoallelic expression underlies reduced penetrance in inherited GATA2-mutated MDS/AML. Leukemia, 2018, 32, 2502-2507.	7.2	48

#	Article	IF	Citations
37	Homozygous OB-fold variants in telomere protein TPP1 are associated with dyskeratosis congenitaâ€“like phenotypes. Blood, 2018, 132, 1349-1353.	1.4	16
38	Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations. Epigenetics, 2017, 12, 370-377.	2.7	31
39	Familial CEBPA -mutated acute myeloid leukemia. Seminars in Hematology, 2017, 54, 87-93.	3.4	54
40	Recurrent somatic JAK-STAT pathway variants within a RUNX1-mutated pedigree. European Journal of Human Genetics, 2017, 25, 1020-1024.	2.8	13
41	Follicular lymphoma: Stateâ€ofâ€theâ€art ICML workshop in Lugano 2015. Hematological Oncology, 2017, 35, 397-407.	1.7	11
42	Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors. Nature Cell Biology, 2017, 19, 1093-1104.	10.3	58
43	Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells. Leukemia, 2017, , .	7.2	0
44	The molecular pathogenesis of the NUP98-HOXA9 fusion protein in acute myeloid leukemia. Leukemia, 2017, 31, 2000-2005.	7.2	28
45	The routes for transformation of follicular lymphoma. Current Opinion in Hematology, 2016, 23, 385-391.	2.5	16
46	Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. Blood, 2016, 128, 2666-2670.	1.4	82
47	Germline heterozygous DDX41 variants in a subset of familial myelodysplasia and acute myeloid leukemia. Leukemia, 2016, 30, 2083-2086.	7.2	62
48	TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses. Blood, 2016, 128, 72-81.	1.4	29
49	Inherited DDX41 mutations: 11 genes and counting. Blood, 2016, 127, 960-961.	1.4	21
50	Pediatric-type FL: simply different. Blood, 2016, 128, 1030-1031.	1.4	2
51	Advances in the molecular diagnosis of diffuse large B-cell lymphoma in the era of precision medicine. Expert Review of Molecular Diagnostics, 2016, 16, 1093-1102.	3.1	3
52	The International Human Epigenome Consortium: A Blueprint for Scientific Collaboration and Discovery. Cell, 2016, 167, 1145-1149.	28.9	404
53	Clinical utility gene card for: Familial platelet disorder with associated myeloid malignancies. European Journal of Human Genetics, 2016, 24, 3-4.	2.8	5
54	5. Follicular lymphoma. , 2016, , 75-100.		0

#	Article	IF	Citations
55	Reduced Expression of Histone Methyltransferases KMT2C and KMT2D Correlates with Improved Outcome in Pancreatic Ductal Adenocarcinoma. Cancer Research, 2016, 76, 4861-4871.	0.9	72
56	DNAJC21 Mutations Link a Cancer-Prone Bone Marrow Failure Syndrome to Corruption in 60S Ribosome Subunit Maturation. American Journal of Human Genetics, 2016, 99, 115-124.	6.2	85
57	Epigenetic dysregulation in follicular lymphoma. Epigenomics, 2016, 8, 77-84.	2.1	20
58	Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. Nature Genetics, 2016, 48, 183-188.	21.4	160
59	Early Loss of CREBBP Confers Malignant Stem Cell Properties on Lymphoid Progenitors. Blood, 2016, 128, 460-460.	1.4	1
60	ÎFÎšÎ'Î™Î• Deletions: A Novel Marker of Clinical Aggressiveness in Primary Mediastinal B-Cell Lymphoma. Blood, 2016, 128, 609-609.	1.4	0
61	Disease evolution and outcomes in familial AML with germline CEBPA mutations. Blood, 2015, 126, 1214-1223.	1.4	157
62	High Throughput Sequencing Analysis of the Immunoglobulin Heavy Chain Gene from Flow-Sorted B Cell Sub-Populations Define the Dynamics of Follicular Lymphoma Clonal Evolution. PLoS ONE, 2015, 10, e0134833.	2.5	28
63	A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma. Genome Medicine, 2014, 6, 105.	8.2	106
64	Myeloblative therapy with autologous haematopoietic stem cell support as consolidation of first remission in acute myeloid leukaemia â€“ very long followâ€up. British Journal of Haematology, 2014, 167, 724-726.	2.5	4
65	Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nature Genetics, 2014, 46, 176-181.	21.4	624
66	Investigational epigenetically targeted drugs in early phase trials for the treatment of haematological malignancies. Expert Opinion on Investigational Drugs, 2014, 23, 1321-1332.	4.1	7
67	Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. Blood, 2014, 123, 1681-1690.	1.4	110
68	<scp>GATA</scp>2 mutations in sporadic and familial acute myeloid leukaemia patients with <scp>CEBPA</scp> mutations. British Journal of Haematology, 2013, 161, 701-705.	2.5	47
69	Highly variable clinical manifestations in a large family with a novel GATA2 mutation. Leukemia, 2013, 27, 2247-2248.	7.2	27
70	EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood, 2013, 122, 3165-3168.	1.4	274
71	The co-receptor BTLA negatively regulates human VÎ³9VÎ´2 T-cell proliferation: a potential way of immune escape for lymphoma cells. Blood, 2013, 122, 922-931.	1.4	87
72	Functional Analysis of a Breast Cancer-Associated FGFR2 Single Nucleotide Polymorphism Using Zinc Finger Mediated Genome Editing. PLoS ONE, 2013, 8, e78839.	2.5	14

#	Article	IF	Citations
73	Investigating The Role Of MLL2 (Mll4) In B Cell Development. Blood, 2013, 122, 343-343.	1.4	0
74	Familial AML With Germline CEBPA Mutations: Extended Clinical Outcomes and Analysis Of Secondary Mutations Using Whole Exome Sequencing. Blood, 2013, 122, 740-740.	1.4	0
75	Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival. Haematologica, 2012, 97, 890-894.	3.5	85
76	Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis. Cell Death and Disease, 2012, 3, e342-e342.	6.3	107
77	Overexpression of wild-type or mutants forms of CEBPA alter normal human hematopoiesis. Leukemia, 2012, 26, 1537-1546.	7.2	23
78	BLUEPRINT to decode the epigenetic signature written in blood. Nature Biotechnology, 2012, 30, 224-226.	17.5	323
79	High Incidence of EZH2 Mutations with Variable Mutation Load in Follicular Lymphoma and Its Consequences for EZH2 Targeted Therapy. Blood, 2012, 120, 545-545.	1.4	0
80	Whole Genome Sequencing in Sequential Biopsies Reveals the Genetic Evolution of Follicular Lymphoma to Transformed Follicular Lymphoma. Blood, 2012, 120, 145-145.	1.4	0
81	SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma. Blood, 2011, 117, 3147-3150.	1.4	17
82	MicroRNA profiles of t(14;18)â€“negative follicular lymphoma support a late germinal center B-cell phenotype. Blood, 2011, 118, 5550-5558.	1.4	77
83	It's a targeted world in non-Hodgkin's lymphoma. British Journal of Nursing, 2011, 20, S28-S28.	0.7	1
84	Serum selenium concentration at diagnosis and outcome in patients with haematological malignancies. British Journal of Haematology, 2011, 154, 448-456.	2.5	20
85	EZH2 Y641 mutations in follicular lymphoma. Leukemia, 2011, 25, 726-729.	7.2	132
86	Transformation of Indolent B-Cell Lymphomas. Journal of Clinical Oncology, 2011, 29, 1827-1834.	1.6	164
87	The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemia. Hematological Oncology, 2010, 28, 13-19.	1.7	38
88	Molecular signatures in the diagnosis and management of follicular lymphoma. Current Opinion in Hematology, 2010, 17, 333-340.	2.5	8
89	A novel RUNX1 mutation in a kindred with familial platelet disorder with propensity to acute myeloid leukaemia: male predominance of affected individuals. European Journal of Haematology, 2010, 85, 552-553.	2.2	13
90	AZD1152 Rapidly and Negatively Affects the Growth and Survival of Human Acute Myeloid Leukemia Cells In vitro and In vivo. Cancer Research, 2009, 69, 4150-4158.	0.9	72

#	Article	IF	Citations
91	Array-based DNA methylation profiling in follicular lymphoma. Leukemia, 2009, 23, 1858-1866.	7.2	65
92	Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood, 2009, 114, 826-834.	1.4	177
93	Clinical relevance of MDM2 SNP 309 and TP53 Arg72Pro in follicular lymphoma. Haematologica, 2009, 94, 148-150.	3.5	18
94	Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone. Blood, 2009, 113, 3553-3557.	1.4	129
95	Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. Blood, 2009, 113, 2298-2301.	1.4	75
96	Familial myelodysplasia and acute myeloid leukaemia â€“ a review. British Journal of Haematology, 2008, 140, 123-132.	2.5	159
97	Mutation of the Wilmsâ€™ Tumor 1 Gene Is a Poor Prognostic Factor Associated With Chemotherapy Resistance in Normal Karyotype Acute Myeloid Leukemia: The United Kingdom Medical Research Council Adult Leukaemia Working Party. Journal of Clinical Oncology, 2008, 26, 5429-5435.	1.6	185
98	Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia. Blood, 2008, 112, 814-821.	1.4	97
99	The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood, 2008, 112, 3126-3129.	1.4	112
100	Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood, 2008, 112, 4639-4645.	1.4	222
101	WTX is rarely mutated in acute myeloid leukemia. Haematologica, 2008, 93, 947-948.	3.5	10
102	Five New Pedigrees with Inherited RUNX1 Mutations Causing Familial Platelet Disorder with Propensity to Myeloid Malignancy (FPD/AML). Blood, 2008, 112, 5067-5067.	1.4	0
103	Recurrent Chromosomal Intermingling Interactions at the BCL2 Locus in T(14;18) +Ve and â^'Ve Cell Lines.. Blood, 2008, 112, 2048-2048.	1.4	0
104	Genetic Abnormalities Involved in the Development and Progression of Follicular Lymphoma.. Blood, 2008, 112, 2049-2049.	1.4	0
105	Role of Different C/EBPÎ± Mutations in AML Transformation.. Blood, 2008, 112, 1343-1343.	1.4	0
106	Chemosensitization of B-Cell Lymphomas by Methylseleninic Acid Involves Nuclear Factor-ÎºB Inhibition and the Rapid Generation of Other Selenium Species. Cancer Research, 2007, 67, 10984-10992.	0.9	41
107	Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia, 2007, 21, 550-551.	7.2	88
108	Genome-wide detection of recurring sites of uniparental disomy in follicular and transformed follicular lymphoma. Leukemia, 2007, 21, 1514-1520.	7.2	78

#	Article	IF	Citations
109	Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. British Journal of Haematology, 2007, 136, 286-293.	2.5	142
110	Should Patients with Myelodysplasia and/or Acute Myeloid Leukemia (MDS/AML) Be Screened for Inherited RUNX1 Mutations Prior to Sibling Donor Allografting?.. Blood, 2007, 110, 5027-5027.	1.4	0
111	Development of a quantitative real-time polymerase chain reaction method for monitoring CEBPA mutations in normal karyotype acute myeloid leukaemia. British Journal of Haematology, 2006, 133, 060203080756008.	2.5	16
112	A novel K509I mutation of KIT identified in familial mastocytosisâ€"in vitro and in vivo responsiveness to imatinib therapy. Leukemia Research, 2006, 30, 373-378.	0.8	129
113	The activity of methylated and non-methylated selenium species in lymphoma cell lines and primary tumours. Annals of Oncology, 2006, 17, 773-779.	1.2	35
114	Wilmâ€™s Tumour 1 (WT1) Mutations Are Associated with FLT3-ITD Mutation and Poor Prognosis in Normal Karyotype AML.. Blood, 2006, 108, 2302-2302.	1.4	0
115	aUPD in the Clonal Evolution of Follicular Lymphoma.. Blood, 2006, 108, 2065-2065.	1.4	0
116	Development of a human acute myeloid leukaemia screening panel and consequent identification of novel gene mutation in FLT3 and CCND3. British Journal of Haematology, 2005, 128, 318-323.	2.5	25
117	A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma. Leukemia, 2005, 19, 1459-1465.	7.2	58
118	Mutations of the PU.1 Ets domain are specifically associated with murine radiation-induced, but not human therapy-related, acute myeloid leukaemia. Oncogene, 2005, 24, 3678-3683.	5.9	58
119	Association between Acquired Uniparental Disomy and Homozygous Gene Mutation in Acute Myeloid Leukemias. Cancer Research, 2005, 65, 9152-9154.	0.9	221
120	The Activity of the Novel Aurora Kinase B Inhibitor AZD1152 in Acute Myeloid Leukaemia Cells.. Blood, 2005, 106, 3374-3374.	1.4	12
121	Methylseleninic Acid Results in Rapid Changes in Intracellular Selenium Species and Sensitises Human Lymphoma Cells to Doxorubicin.. Blood, 2005, 106, 1768-1768.	1.4	0
122	Reliable detection of clonal IgH/Bcl2 MBR rearrangement in follicular lymphoma: methodology and clinical significance. British Journal of Haematology, 2004, 124, 325-328.	2.5	16
123	Mutation ofCEBPAin Familial Acute Myeloid Leukemia. New England Journal of Medicine, 2004, 351, 2403-2407.	27.0	295
124	Tissue Microarray Is a Useful Tool in the Evaluation of Genes Implicated in Transformation of Follicular Lymphoma.. Blood, 2004, 104, 2267-2267.	1.4	1
125	Sequential Time-Point Mutational Analysis of TP53 in Follicular Lymphoma Undergoing Transformation to Large B-Cell Lymphoma.. Blood, 2004, 104, 1361-1361.	1.4	12
126	The Induction of Apoptosis in Lymphoma Cells by Methylseleninic Acid and Selenodiglutathione.. Blood, 2004, 104, 2502-2502.	1.4	0

#	Article	IF	Citations
127	Mutation of CEBPA in Familial Acute Myeloid Leukaemia.. Blood, 2004, 104, 2012-2012.	1.4	0
128	Development of a Human Acute Myeloid Leukaemia Screening Panel and Identification of Novel Gene Mutations.. Blood, 2004, 104, 2991-2991.	1.4	0
129	Flow Cytometric FLT3 Expression in Acute Leukaemias Is of Diagnostic Value but Does Not Correlate with ITD / D835Y Mutation Status.. Blood, 2004, 104, 3014-3014.	1.4	0
130	Mutations ofCEBPA in acute myeloid leukemia FAB types M1 and M2. Genes Chromosomes and Cancer, 2003, 37, 72-78.	2.8	98
131	Mutation of BRAF is uncommon in AML FAB type M1 and M2. Leukemia, 2003, 17, 274-275.	7.2	23
132	Presentation Serum Selenium Predicts for Overall Survival, Dose Delivery, and First Treatment Response in Aggressive Non-Hodgkinâ€™s Lymphoma. Journal of Clinical Oncology, 2003, 21, 2335-2341.	1.6	56
133	Mutations in the runt homology domain of CBFÎ±2 in myeloid malignancies with acquired trisomy 21. Cancer Genetics and Cytogenetics, 2002, 136, 151-152.	1.0	6
134	JH probe real-time quantitative polymerase chain reaction assay for Bcl-2/IgH rearrangements. British Journal of Haematology, 2002, 118, 550-558.	2.5	12
135	The relative role of peripheral blood and bone marrow for monitoring molecular evidence of disease in follicular lymphoma by quantitative real-time polymerase chain reaction. British Journal of Haematology, 2002, 118, 563-566.	2.5	15
136	Frequency of the Bcl-2/IgH Rearrangement in Normal Individuals: Implications for the Monitoring of Disease in Patients With Follicular Lymphoma. Journal of Clinical Oncology, 2001, 19, 420-424.	1.6	137
137	Localisation of a novel region of recurrent amplification in follicular lymphoma to an ?6.8 Mb region of 13q32-33. Genes Chromosomes and Cancer, 2001, 32, 236-243.	2.8	40
138	Familial follicular lymphoma: A Case Report with Molecular Analysis. British Journal of Haematology, 2000, 110, 744-745.	2.5	2
139	Tumour necrosis factor polymorphisms and susceptibility to follicular lymphoma. British Journal of Haematology, 1999, 107, 388-391.	2.5	25
140	Isolation and Chromosomal Localization of Two Human CDP-diacylglycerol Synthase (CDS) Genes. Genomics, 1998, 54, 140-144.	2.9	44
141	Molecular Evolution of the Cottoid Fish Endemic to Lake Baikal Deduced from Nuclear DNA Evidence. Molecular Phylogenetics and Evolution, 1997, 8, 415-422.	2.7	39
142	Spectral tuning and molecular evolution of rod visual pigments in the species flock of cottoid fish in Lake Baikal. Vision Research, 1996, 36, 1217-1224.	1.4	129
143	Human guanylate kinase (GUK1): cDNA sequence, expression and chromosomal localisation. FEBS Letters, 1996, 385, 185-188.	2.8	17
144	Paralogy Mapping: Identification of a Region in the Human MHC Triplicated onto Human Chromosomes 1 and 9 Allows the Prediction and Isolation of NovelPBXandNOTCHLoci. Genomics, 1996, 35, 101-108.	2.9	161

#	Article	IF	Citations
145	Localisation of the gene encoding diacylglycerol kinase 3 (DAGK3) to human chromosome 3q27-28 and mouse chromosome 16. Current Eye Research, 1995, 14, 1041-1043.	1.5	1
146	The rhodopsin-encoding gene of bony fish lacks introns. Gene, 1995, 164, 273-277.	2.2	77
147	Chromosomal localization of three mouse diacylglycerol kinase (DAGK) genes: genes sharing sequence homology to the Drosophila retinal degeneration A (rdgA) gene. Genomics, 1995, 26, 599-601.	2.9	12
148	Regional Localization of 64 Cosmid Contigs, Including 18 Genes and 14 Markers, to Intervals on Human Chromosome 9q34. Genomics, 1995, 29, 257-260.	2.9	5
149	Drosophila Visual Transduction, a Model System For Human Eye Disease?. , 1995, , 255-261.		1
150	Cosmid Contigs Spanning 9q34 Including the Candidate Region forTSCI. European Journal of Human Genetics, 1995, 3, 65-77.	2.8	9
151	Localization of the gene encoding human phosphatidylinositol transfer protein (PITPN) to 17p13.3: a gene showing homology to the Drosophila retinaldegeneration B gene (rdgB). Cytogenetic and Genome Research, 1994, 67, 205-207.	1.1	8
152	Localisation of the human blue cone pigment gene to chromosome band 7q31.3-32. Human Genetics, 1994, 93, 79-80.	3.8	18
153	Localization of the retinoid X receptor alpha gene (RXRA) to chromosome 9q34. Annals of Human Genetics, 1993, 57, 195-201.	0.8	7
154	Mapping of RXRB to human chromosome 6p21. 3. Annals of Human Genetics, 1993, 57, 203-209.	0.8	15
155	A dual role for the RNA helicase DHX34 in NMD and pre-mRNA splicing and its function in hematopoietic differentiation. Rna, 0, , rna.079277.122.	3.5	4